New hope for Tough-to-Treat anal and rectal cancers
NCT ID NCT06669572
Summary
This study is testing whether a combination of two drugs, lenvatinib and pembrolizumab, is safe and effective for people with advanced anal or rectal cancer that has spread and is no longer responding to standard chemotherapy. The trial will enroll about 35 adults whose cancer is considered inoperable. The goal is to see if this drug combo can shrink tumors and control the disease for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, SQUAMOUS CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.